Table 2 Baseline demographic and clinical characteristics of patients with bilirubin elevation above 2 mg/dl after allo-HSCT.
Characteristics | All cohort N = 17 | SOS group n = 10 | Non-SOS group n = 7 |
|---|---|---|---|
Age at allogeneic HSCT (years, median, IQR) | 49 (34–62) | 53 (32–66) | 38 (37–58) |
Gender, Male n (%) | 10 (59) | 6 (60) | 4 (57) |
Obesity, n (%) | 3 (17.6) | 2 (20) | 1 (14) |
Hepatic comorbidities, n (%) | |||
Baseline bilirubin | 0.7 (0.6–0.8) | 0.7 (0.6–0.9) | 0.7 (0.6–0.9) |
Fatty liver disease | 1 (7.7) | 0 | 1 (14) |
Alcohol misuse | 1 (7.7) | 0 | 1 (14) |
Portal hypertension | 1 (7.7) | 1 (10) | 0 |
History of multiple blood transfusion | 13 (77) | 8 (80) | 5 (71) |
Ferritin >1000 ng/mla | 5 | 4 | 1 |
Diagnosis, n (%) | |||
MDS/AML | 7 (41) | 4 (40) | 3 (43) |
ALL | 5 (30) | 4 (40) | 1 (14) |
Myelofibrosis | 4 (24) | 2 (20) | 2 (29) |
Lymphoma | 1 (6) | 0 | 1 (14) |
Median Lines of Chemotherapy before HCT | 2 (0–6) | 3 (0–6) | 2 (0–5) |
Previous CTX for other malignancy | 2 pts | 1 | 1 |
Active disease at transplant | 5 (29) | 3 (30) | 2 (29) |
TBI | 4 (24) | 3 (30) | 1(14) |
Conditioning regimen, n (%) | |||
MAC | 5 | 1 | 4 |
BUCY | 2 | 1 | 1 |
CYTBI | 1 | 0 | 1 |
TBF MAC | 1 | 0 | 1 |
FLU TREO14 | 1 | 0 | 1 |
RTC | 5 | 5 | 0 |
FLU TREO12 | 2 | 2 | 0 |
FLUBU4 | 1 | 1 | 0 |
TBI FLU with PT-CY | 2 | 2 | 0 |
RIC | 7 | 4 | 3 |
FLU TREO10 | 2 | 1 | 1 |
FLUBU2 | 1 | 1 | 0 |
TBF RIC | 4 | 2 | 2 |
DAC | 5 | 2 | 3 |
GO Tx | 1 | 1 | 0 |
Ino Tx | 2 | 2 | 0 |
